Moneycontrol PRO
HomeAuthorAnubhav sahu News

Anubhav Sahu

Special Analyst

Moneycontrol Research

Divi’s Lab: Progress in product launch pipeline adds to conviction

BUSINESS

Divi’s Lab: Progress in product launch pipeline adds to conviction

Sequential improvement in margin on the back of a favourable product mix and lower raw material prices

Entero IPO: Should investors pop the flotation pill?

BUSINESS

Entero IPO: Should investors pop the flotation pill?

The company will have to scale up its top line manifold to be able to protect its profitability

Tata Consumer Products: Resilient performance of new businesses with margin beat

BUSINESS

Tata Consumer Products: Resilient performance of new businesses with margin beat

Premium products, operating leverage, and merger synergies to aid further growth

Navin Fluorine: Going through transitional pain of de-stocking and deferrals

BUSINESS

Navin Fluorine: Going through transitional pain of de-stocking and deferrals

The capex announcement for the new cGMP facility, supply agreement with Fermion, and a strategic partnership with a US-based CDMO player indicate that the company is on track to reach the goal of $100 million for the CDMO business.

SRF: Last leg of inventory rationalisation provides an opportunity

BUSINESS

SRF: Last leg of inventory rationalisation provides an opportunity

The management sees a sharp sequential recovery as channel inventory and pricing situation are stabilising. Further, new capacities for varied product categories are expected to contribute in the coming months.

Sun Pharma: Superior execution makes us constructive

BUSINESS

Sun Pharma: Superior execution makes us constructive

Progress in the specialty pipeline is encouraging

Higher R&D allocation in Budget to boost discovery of new molecules

BUSINESS

Higher R&D allocation in Budget to boost discovery of new molecules

Focus on R&D should be positive for the research focused companies particularly from the domains of biotech, oncology, battery chemicals and green energy.

Fed policy: Base case is for rate cuts, but the question is when

BUSINESS

Fed policy: Base case is for rate cuts, but the question is when

While the case for soft landing gets stronger, Fed is in no hurry to cut rates

Syngene: Weak funding environment leads to a soft patch

BUSINESS

Syngene: Weak funding environment leads to a soft patch

The research division proves to be a drag while manufacturing turns out to be the saviour

Laurus Labs: CDMO ramp-up has some runway ahead before it flies

BUSINESS

Laurus Labs: CDMO ramp-up has some runway ahead before it flies

The company’s investment in new-age technologies and talent, which shall pay back in a longer timeframe, is the chief reason to remain invested in it.

Nova Agritech IPO: Hunting for high growth capital, eyes ‘one-stop solution provider’ tag

BUSINESS

Nova Agritech IPO: Hunting for high growth capital, eyes ‘one-stop solution provider’ tag

The sustainability of margins and the growth trajectory will be key factors to watch

Aarti Industries: Increasing share of long-term contracts

BUSINESS

Aarti Industries: Increasing share of long-term contracts

The company’s existing long-term contracts can potentially generate more than one-third of the revenue it generated in FY23. As new plants and products get commissioned, Aarti would increase the share of longer-term contracts

Discovery Series: New capacity, R&D uptrend to kickstart new earnings cycle for this healthcare proxy

TRENDS

Discovery Series: New capacity, R&D uptrend to kickstart new earnings cycle for this healthcare proxy

Tarsons Products is well positioned to gain from the surge in R&D investments in new molecules in the labware industry and demand for diagnostic services.

Aarti Industries: Sequential improvements support investment case

BUSINESS

Aarti Industries: Sequential improvements support investment case

Though long-term contracts have been a mixed bag for the company so far, as and when new plants and products get commissioned, Aarti would increase the share of such contracts.

Syngene: Preferred CRAMS play for the long term

BUSINESS

Syngene: Preferred CRAMS play for the long term

The company’s underperformance, compared to the Nifty, is not justified, and there is merit in considering the stock at the current levels. In the medium term, complex APIs and biologics manufacturing would be the growth drivers.

Ami Organics: Multiple growth catalysts taking shape

BUSINESS

Ami Organics: Multiple growth catalysts taking shape

Ami Organics is making its mark in the niche segments of chemicals having applications in lithium-ion batteries and semiconductors.

Innova Captab IPO: A pricey contract manufacturer

BUSINESS

Innova Captab IPO: A pricey contract manufacturer

The prime driver of growth is the volume visibility from contract duration, which is typically in the range of 2-5 years

Equity strategy: Is a spoiler in the making for the Santa Claus rally?

BUSINESS

Equity strategy: Is a spoiler in the making for the Santa Claus rally?

The emerging Suez trade channel crisis might rekindle inflation fears. Advanced economies are already facing a sharp deceleration in growth indicators

Fed policy: Dot plot suggests a pivot towards rate cuts

BUSINESS

Fed policy: Dot plot suggests a pivot towards rate cuts

Domestic interest sensitive sectors can have positive rub-off

Is the time ripe to add position in this chemical stock?

BUSINESS

Is the time ripe to add position in this chemical stock?

The company stands out due to the contractual nature of some of its businesses despite an adverse demand-supply situation

Mandatory ACs in trucks: Multiple companies to benefit from the move

BUSINESS

Mandatory ACs in trucks: Multiple companies to benefit from the move

With the outlook for commercial vehicles remaining positive, Subros, Amber, SRF, and Navin Flurine will be gainers

Himadri Speciality: Carbon companies scouting for new growth levers

BUSINESS

Himadri Speciality: Carbon companies scouting for new growth levers

Announces plan to set up India’s first commercial plant for Lithium Ion Phosphate Cathode Active Material.

Balaji Amines: How long would destocking continue?

BUSINESS

Balaji Amines: How long would destocking continue?

While the company may face pricing pressure in the next few quarters, it continues to target new products under the import substitution strategy. This augurs well for investors

Equity strategy — How will the market react to state election results?

BUSINESS

Equity strategy — How will the market react to state election results?

Improved political stability is a positive factor indeed, but elevated valuations mean they will seek support in earnings momentum even though global volatility lurks in the background

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347